Organizing and tracking the lifecycle of novel biological modalities

Posted by
Mark Somogyi
on 11 11 2022

An ongoing trend in the life sciences industry is the development of a diverse range of biomodalities. Until 2021, almost half of the approved drugs belonged to these biological entity classes.

Synthetic biomolecules are an especially important class of biomodalities which take advantage of the continuously increasing chemistry space accessible to scientists in order to improve their properties such as potency, stability and permeability.

Biomolecular drugs and biologics can be used to specifically treat disease targets, even those which were considered “undruggable” using small molecule drugs.

 

Learn more